Amgen Inc. is betting that Bind Biosciences Inc.'s Accurin nanotechnology can overcome one of the major limitations for kinase inhibitors in cancer: the fact that these drugs affect healthy and cancerous cells equally. The pair partnered this month to see whether the Accurin technology can target an undisclosed kinase inhibitor from Amgen to cancerous cells in solid tumors.

According to Bind President and CEO Scott Minick, if the companies are successful, the compound would be the first tissue- and cellular-targeted kinase inhibitor in the clinic.